Tech Scouting Requirements

We are looking for NAT platforms in the following categories:

Disease Focus Areas

• Oncology

• Metabolic Diseases

(Both areas share the same technology interests.)

Technology Interests

• siRNA (Small Interfering RNA): Gene-silencing platforms targeting disease-driving genes with high specificity and efficiency.

• Antisense Oligonucleotides (ASOs): Precision modulators of gene expression with improved chemical stability and delivery potential.

• mRNA Therapeutics: Platforms that either suppress or indue protein expression for therapeutic effect, with innovations in delivery, translation efficiency, and immune tolerability.

Required Stage:

• In vivo efficacy data required.

• Preferred: Supporting non-GLP or GLP toxicity data.

Problem Statement

Nucleic acid therapeutics have emerged as a powerful tool for precision medicine, yet challenges remain in delivery, durability, and off-target effects. Celltrion is seeking NAT platforms with optimized design and delivery characteristics that can overcome these hurdles in oncology and metabolic indications, with an emphasis on strong in vivo validation and clinical translation potential.

Why Apply?

This is a compelling opportunity to collaborate with Celltrion, a biopharmaceutical leader who developed the first biosimilar with deep expertise in drug development and biologics manufacturing. Celltrion is open to worldwide partnerships beyond the APAC region, offering selected innovators access to co-development, investment, licensing, and commercialization opportunities. Join us in shaping the next wave of nucleic acid based platforms that can transform lives and redefine care standards.

Submissions close on 30 June

Apply now and unlock the full potential of nucleic acid therapeutics in the treatment of cancer and metabolic diseases.

For inquiries, please contact startup.relations@ventureblick.com

创新具体要求

我们正在寻找以下类别的核酸疗法：

重点疾病领域

• 肿瘤

• 代谢性疾病

（不同的应用领域，相同的技术方向）

技术方向

• siRNA（小干扰RNA）：针对致病基因、具有高特异性和高效率的基因沉默平台。

• 反义寡核苷酸（ASO）：具有更高化学稳定性和递送潜力，实现基因表达的精准调控。

• mRNA 疗法：通过抑制或诱导蛋白质表达来达到治疗效果的平台，在递送、翻译效率和免疫耐受性方面具有创新性。

阶段要求：

• 需提供体内有效性数据。

• 优先考虑：有非GLP或GLP毒性试验数据。

当前挑战

核酸疗法已成为精准医疗的有力工具，但在药物递送、耐久性和脱靶效应方面仍存在挑战。Celltrion 正在寻找优化了设计和递送特性、能克服治疗肿瘤和代谢适应症时的这些障碍，并拥有突出的体内验证结果和临床转化潜力的核酸疗法平台。

为何申请？

这是与领先的生物制药跨国公司 Celltrion 合作的一个绝佳机会。Celltrion 是世界上首个单克隆抗体生物类似药的开发者，拥有药物开发和生物制剂生产的深厚能力。Celltrion 积极在亚太地区乃至全球探索合作，将为其选择的创新伙伴提供共同开发、投资、许可和商业化的多种潜在机会。与我们携手，塑造下一代核酸药物疗法，刷新护理标准并点亮生命希望。

申请提交截止日：6 月 30 日

立即申请，解锁核酸疗法在癌症和代谢性疾病治疗中的全面潜力。

如需咨询更多信息，请发送邮件至 startup.relations@ventureblick.com